UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________
FORM 8-K
______________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 29, 2014
Nuo Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
______________
| Delaware | 01-32518 | 23-3011702 |
| (State or Other Jurisdiction | (Commission | (I.R.S. Employer |
| of Incorporation) | File Number) | Identification No.) |
207A Perry Parkway, Suite 1, Gaithersburg, MD 20877
(Address of Principal Executive Office) (Zip Code)
240-499-2680
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers
On December 29, 2014, Richard Kent informed the Company of his resignation from the Board of Directors (the “Board”) of Nuo Therapeutics, Inc. (the “Company”), with the effective date of his departure of December 31, 2014. Mr. Kent was an independent member of the Board and a member of the Board’s Compensation Committee. His decision to resign was not for cause or due to or resulting from any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
The Company thanks Mr. Kent for years of service on the Company’s Board and wishes him well in his future professional and personal endeavors.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| Nuo Therapeutics, Inc. | |||
| By: | /s/ Martin P. Rosendale | ||
| Martin P. Rosendale, Chief Executive Officer | |||
Date: December 31, 2014